Skip to main content

Table 2 Barriers to use of MgSO4 for fetal neuroprotection (N (%) responses for all responses that relate to barriers)

From: Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada

Nodes Sub-nodes e-learning module (N = 119) Site visits (N = 92) Barriers & Facilitators Survey (N = 147)
Individual-level 51 (42.9 %) 47 (51.1 %) 86 (58.5 %)
 Unsupportive attitudes and beliefs 12 (10.1 %) 3 (3.3 %) 12 (8.2 %)
 Not within provider’s control 4 (3.4 %) 0 2 (1.4 %)
 No experience 3 (2.5 %) 1 (1.1 %) 3 (2.0 %)
 Inadequate knowledge and understanding Overall 15 (12.6 %) 18 (19.6 %) 35 (23.8 %)
 In self 0 3 18
 In others 13 4 9
 Unclear who lacks knowledge 2 11 8
 Forgetting to administer MgSO4 1 (0.8 %) 1 (1.1 %) 3 (2.0 %)
 Fears Overall 14 (11.8 %) 16 (17.4 %) 13 (8.8 %)
 Legal 0 2 3
 Medication error 0 2 0
 Adverse effects of withholding MgSO 4 0 3 5
 Adverse effects of MgSO 4 14 9 5
 Failure to implement guidelines 0 1 (1.1 %)) 4 (2.7 %)
 Evidence concerns (sufficiency and validity) 2 (1.7 %) 7 (7.6 %) 14 (9.5 %)
Institutional-level 64 (53.8 %) 34 (37.0 %) 40 (27.2 %)
 Unsupportive institutional culture 2 (1.7 %) 3 (3.3 %) 3 (2.0 %)
 Timing and transport 20 (16.8 %) 17 (18.5 %) 6 (4.1 %)
 Resource constraints 31 (25.2 %) 12 (13.0 %) 20 (13.6 %)
 Policy development and implementation 11 (9.2 %) 2 (12.0 %) 11 (7.5 %)
Social-level 4 (3.4 %) 11 (12.0 %) 21 (14.3 %)
 Lack of provider-institutional consensus 1 (0.8 %) 4 (4.3 %) 15 (10.2 %)
 Inadequate interprovider communication 0 7 (7.6 %) 5 (3.4 %)
 Educating patients 3 (2.5 %) 0 1 (0.7 %)
  1. MgSO4 (magnesium sulphate)
  2. Note that the total % is broken down in various ways; each area until a bolded row adds to the % listed in the bolded row